Saito Ayumi, Yonemori Kan
Dept. of Medical Oncology, National Cancer Center Hospital.
Gan To Kagaku Ryoho. 2024 Jul;51(7):695-701.
Antibody-drug conjugates(ADCs)have become widely used in the treatment of various malignancies over the past 15 years. In breast cancer, T-DM1 and T-DXd which is HER2-targeted ADC have been approved and are broadly used in Japan. Sacituzumab govitecan, TROP2-ADC has been approved in US. Hence, multiple ADCs could be used for breast cancer treatment. In gynecological cancers, tisotumab vedotin for cervical cancer and mirvetuximab soravtansine for ovarian cancer have been approved in the US. Optimizing treatment sequences and overcoming resistance mechanisms for ADC are important challenges in the situations where multiple ADCs are available. The current development landscape suggests further enhancement of ADC treatment efficacy through new targets, novel payloads, bispecific ADCs, and combination therapies with immunotherapy. This article outlines the current status of ADCs in breast and gynecological cancers, highlighting ongoing development and challenges emerging in the field.
在过去15年中，抗体药物偶联物（ADCs）已广泛应用于各种恶性肿瘤的治疗。在乳腺癌治疗中，靶向HER2的ADC药物曲妥珠单抗-美坦新偶联物（T-DM1）和德曲妥珠单抗（T-DXd）已获批准并在日本广泛使用。戈沙妥珠单抗（Sacituzumab govitecan），一种靶向滋养层细胞表面抗原2（TROP2）的ADC药物，已在美国获批。因此，多种ADC药物可用于乳腺癌治疗。在妇科癌症治疗方面，用于宫颈癌的替索单抗维布妥昔单抗（tisotumab vedotin）和用于卵巢癌的mirvetuximab soravtansine已在美国获批。在有多种ADC药物可用的情况下，优化治疗顺序和克服ADC药物的耐药机制是重要挑战。当前的发展态势表明，通过新靶点、新型有效载荷、双特异性ADC药物以及与免疫疗法的联合治疗，ADC药物的治疗效果将得到进一步提升。本文概述了ADC药物在乳腺癌和妇科癌症治疗中的现状，重点介绍了该领域正在进行的研发情况以及面临的挑战。
